Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Liabilities (2018 - 2025)

Summit Therapeutics' Total Liabilities history spans 8 years, with the latest figure at $69.5 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 6.98% year-over-year to $69.5 million; the TTM value through Sep 2025 reached $69.5 million, up 6.98%, while the annual FY2024 figure was $46.8 million, 62.63% down from the prior year.
  • Total Liabilities reached $69.5 million in Q3 2025 per SMMT's latest filing, up from $64.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $537.5 million in Q4 2022 to a low of $22.1 million in Q3 2022.
  • Average Total Liabilities over 5 years is $98.1 million, with a median of $64.9 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 1686.35% in 2022, then crashed 76.7% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $30.1 million in 2021, then surged by 1686.35% to $537.5 million in 2022, then plummeted by 76.7% to $125.3 million in 2023, then tumbled by 62.63% to $46.8 million in 2024, then skyrocketed by 48.39% to $69.5 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Total Liabilities are $69.5 million (Q3 2025), $64.6 million (Q2 2025), and $39.5 million (Q1 2025).